Edgewise Therapeutics
Lindsey Lee, Ph.D. has a diverse work experience in scientific research. They currently work at Edgewise Therapeutics as a Scientist I, starting in 2022. Prior to that, from 2016 to 2022, they held various roles at the University of Colorado Boulder. These roles included being a Postdoctoral Research Associate and a Graduate Research Assistant in the Molecular, Cellular, and Developmental Biology PhD Program. In their research, they focused on understanding the biology of a muscle myosin motor protein called MYH7b and its functional effects. They have publications, presented seminars and posters, and mentored students during this time. Before their time at the University of Colorado Boulder, from 2014 to 2016, they worked as a Research Technician at the University of Minnesota. In this role, they conducted experiments related to identifying genetic pathways in cancer and manipulating cancer signaling pathways. They have publications and made poster presentations during this time. Additionally, they worked as an Undergraduate Researcher at St. Olaf College in 2013 and at the Medical College of Wisconsin in 2013.
Lindsey Lee, Ph.D., completed their Bachelor of Arts (B.A.) degree in Biology, graduating with departmental distinction, from St. Olaf College in the years 2010 to 2014. Lindsey then pursued their Doctor of Philosophy (Ph.D.) degree in Molecular, Cellular, and Developmental Biology at the University of Colorado Boulder from 2016 to 2022.
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.